The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Open accessAbstract
BACKGROUND: Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many myeloproliferative neoplasms, but the molecular pathogenesis of myeloproliferative neoplasms with nonmutated JAK2 is obscure, and the diagnosis of these neoplasms remains a challenge. METHODS: We performed exome sequencing of samples obtained from 151 patients with myeloproliferative neoplasms. The mutation status of the gene encoding calreticulin (CALR) was assessed in an additional 1345 hematologic cancers, 1517 other cancers, and 550 controls. We established phylogenetic trees using hematopoietic colonies. We assessed calreticulin subcellular localization using immunofluorescence and flow cytometry. RESULTS: Exome sequencing identified 1498 mutations in 151 patients, with medians of 6.5, 6.5, and 13.0 mutations per patient in samples of polycythemia vera, essential thrombocythemia, and myelofibrosis, respectively. Somatic CALR mutations were found in 70 to 84% of samples of myeloproliferative neoplasms with nonmutated JAK2, in 8% of myelodysplasia samples, in occasional samples of other myeloid cancers, and in none of the other cancers. A total of 148 CALR mutations were identified with 19 distinct variants. Mutations were located in exon 9 and generated a +1 base-pair frameshift, which would result in a mutant protein with a novel C-terminal. Mutant calreticulin was observed in the endoplasmic reticulum without increased cell-surface or Golgi accumulation. Patients with myeloproliferative neoplasms carrying CALR mutations presented with higher platelet counts and lower hemoglobin levels than patients with mutated JAK2. Mutation of CALR was detected in hematopoietic stem and progenitor cells. Clonal analyses showed CALR mutations in the earliest phylogenetic node, a finding consistent with its role as an initiating mutation in some patients. CONCLUSIONS: Somatic mutations in the endoplasmic reticulum chaperone CALR were found in a majority of patients with myeloproliferative neoplasms with nonmutated JAK2. (Funded by the Kay Kendall Leukaemia Fund and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“But many of the most commonly seen mutations in CHIP are also recurrent drivers of AML 64, myelodysplastic syndrome (MDS) 65–67, myeloproliferative neoplasms 68, and certain lymphomas 69,70.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [68]
In the citing paper
“Calreticulin gene (CALR) mutations frequently occur in Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), primary myelofibrosis (PMF), and polycythemia vera (PV) [188–190].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [188]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Self-citationA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,062
Self-citationLevine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationClinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Chao MP, 2010, Sci Transl Med, 2, 63ra94
Cited by
Sorted by citations
Items 501–600 of 1,002
Precision medicine in myeloid malignancies
Westermann, J., & Bullinger, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.034 · Cited by 29
Inferring the initiation and development of myeloproliferative neoplasms
Hermange, G., Rakotonirainy, A., Bentriou, M., Tisserand, A., El-Khoury, M., Girodon, F., Marzac, C., Vainchenker, W., Plo, I., & Cournède, P.-H. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120374119 · Cited by 33
Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).
Luo, W., & Yu, Z. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2306-9759.2015.08.01 · Cited by 29
Minimal residual disease testing in hematologic malignancies and solid cancer
Lassoued, A. B., Nivaggioni, V., & Gabert, J. A. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.927311 · Cited by 29
RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability
Chen, E., Ahn, J. S., Sykes, D. B., Breyfogle, L. J., Godfrey, A. L., Nangalia, J., Ko, A., DeAngelo, D. J., Green, A. R., & Mullally, A. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.037 · Cited by 29
Self-citationNew molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms
Passamonti, F., Mora, B., & Maffioli, M. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000218 · Cited by 29
Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea
Lim, Y., Lee, J., & Bang, S. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.10.1579 · Cited by 30
The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations
Gianelli, U., Cattaneo, D., Bossi, A., Cortinovis, I., Boiocchi, L., Liu, Y.-C., Augello, C., Bonometti, A., Fiori, S., Orofino, N., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.182 · Cited by 29
Molecular testing for JAK 2, MPL , and CALR in myeloproliferative neoplasms
Xia, D., & Hasserjian, R. P. (2016) · American Journal of Hematology · doi:10.1002/ajh.24578 · Cited by 31
Vasko, T., Kaifie, A., Stope, M. B., Kraus, T., & Ziegler, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112267 · Cited by 31
Papadopoulos, N., Nédélec, A., Derenne, A., Şulea, T. A., Pecquet, C., Chachoua, I., Vertenoeil, G., Tilmant, T., Petrescu, A., Mazzucchelli, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37277-3 · Cited by 30
Harada‐Shirado, K., Ikeda, K., Ogawa, K., Ohkawara, H., Kimura, H., Kai, T., Noji, H., Morishita, S., Komatsu, N., & Takeishi, Y. (2014) · British Journal of Haematology · doi:10.1111/bjh.13129 · Cited by 28
Immunotherapy in Myeloproliferative Diseases
Braun, L. M., & Zeiser, R. (2020) · Cells · doi:10.3390/cells9061559 · Cited by 28
Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
Kjær, L. (2020) · Cancers · doi:10.3390/cancers12082100 · Cited by 30
Allain‐Maillet, S., Bosseboeuf, A., Mennesson, N., Bostoën, M., Dufeu, L., Choi, E. H. E., Cleyrat, C., Mansier, O., Lippert, É., Bris, Y. L., et al. (2020) · Cancers · doi:10.3390/cancers12092446 · Cited by 29
Prins, D., Park, H. J., Watcham, S., Li, J., Vacca, M., Bastos, H. P., Gerbaulet, A., Vidal‐Puig, A., Göttgens, B., & Green, A. R. (2020) · Science Advances · doi:10.1126/sciadv.abd3139 · Cited by 30
Self-citationHobbs, G. S., Rozelle, S. S., & Mullally, A. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.04.002 · Cited by 30
Rocca, S., Carrà, G., Poggio, P., Morotti, A., & Brancaccio, M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0774-4 · Cited by 28
Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
Holmström, M. O., Hasselbalch, H. C., & Andersen, M. H. (2020) · Cancers · doi:10.3390/cancers12071763 · Cited by 28
Pemmaraju, N., Gupta, V. K., Mesa, R. A., & Thompson, M. A. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0287-9 · Cited by 27
Safety evaluation of ruxolitinib for treating myelofibrosis
Galli, S., McLornan, D. P., & Harrison, C. N. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.916273 · Cited by 28
Self-citationDahlström, J., Liu, T., Yuan, X., Saft, L., Ghaderi, M., Wei, Y. B., Lavebratt, C., Li, P., Zheng, C., Björkholm, M., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2787-7 · Cited by 27
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study
Perricone, M., Polverelli, N., Martinelli, G., Catani, L., Ottaviani, E., Zuffa, E., Franchini, E., Dizdari, A., Forte, D., Sabattini, E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16744 · Cited by 27
Guglielmelli, P., Pietra, D., Pane, F., Pancrazzi, A., Cazzola, M., Vannucchi, A. M., Tura, S., & Barosi, G. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.04.006 · Cited by 27
Self-citationTaniguchi, Y., Tanaka, H., Luis, E. J., Sakai, K., Kumode, T., Sano, K., Serizawa, K., Rai, S., Morita, Y., Hanamoto, H., et al. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2302-5 · Cited by 27
Pedersen, R. K., Andersen, M., Knudsen, T. A., Sajid, Z., Gudmand‐Hoeyer, J., Dam, M. J. B., Skov, V., Kjær, L., Ellervik, C., Larsen, T. S., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2741 · Cited by 28
Pegliasco, J., Hirsch, P., Marzac, C., Isnard, F., Meniane, J.-C., Deswarte, C., Pellet, P., Lemaitre, C., Leroy, G., Moraes, G. R., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01319-w · Cited by 27
Jutzi, J. S., Marneth, A. E., Jiménez‐Santos, M. J., Hem, J. W., Guerra-Moreno, Á., Rolles, B., Bhatt, S., Myers, S. A., Carr, S. A., Hong, Y., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01781-0 · Cited by 27
Chronic neutrophilic leukemia: a clinical perspective
Cigudosa, J. C., & Menezes, J. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s49688 · Cited by 27
Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling
Eder‐Azanza, L., Navarro, D., Aranaz, P., Novo, F. J., Cross, N. C. P., & Vizmanos, J. L. (2014) · Leukemia · doi:10.1038/leu.2014.190 · Cited by 27
Self-citationAbdulkarim, K., Samuelsson, J., Johansson, P. L., & Andréasson, B. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12873 · Cited by 27
Dutta, A., Hutchison, R. E., & Mohi, G. (2017) · Blood · doi:10.1182/blood-2016-12-757344 · Cited by 27
JAK Inhibitors for Myelofibrosis: Strengths and Limitations
Thaw, K. H., Harrison, C. N., & Sriskandarajah, P. (2024) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-024-00744-9 · Cited by 28
Self-citationQiao, C., Sun, C., Ouyang, Y., Wang, J.-J., Qian, S.-X., Li, J., & Zhang, S. (2014) · Haematologica · doi:10.3324/haematol.2014.109199 · Cited by 26
Self-citationElliott, M. A., & Tefferi, A. (2015) · American Journal of Hematology · doi:10.1002/ajh.24284 · Cited by 26
Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms
Lapoirie, J., Contis, A., Guy, A., Lifermann, F., Viallard, J., Sentilhes, L., James, C., & Duffau, P. (2018) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2018.1484097 · Cited by 26
Battista, V. D., Bochicchio, M. T., Giordano, G., Napolitano, M., & Lucchesi, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020561 · Cited by 27
Morsia, E., Torre, E., Poloni, A., Olivieri, A., & Rupoli, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094573 · Cited by 26
Targeting glutamine metabolism in myeloproliferative neoplasms
Zhan, H., Ciano, K., Dong, K., & Zucker, S. (2015) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2015.07.007 · Cited by 27
Essential Thrombocythemia: The Dermatologic Point of View
Cozzani, E., Iurlo, A., Merlo, G., Cattaneo, D., Burlando, M., Pierri, I., Gugliotta, L., & Parodi, A. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.08.086 · Cited by 26
Peptide Antibodies in Clinical Laboratory Diagnostics
Trier, N. H., & Houen, G. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2017.01.002 · Cited by 26
Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms
Patel, U., Luthra, R., Medeiros, L. J., & Patel, K. P. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.015 · Cited by 26
Gángó, A., Mózes, R., Boha, Z., Kajtár, B., Tímár, B., Király, P. A., Kiss, R., Fésüs, V., Nagy, N., Demeter, J., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2017.12.005 · Cited by 26
Recent advances in the diagnosis and management of primary myelofibrosis
Takenaka, K., Shimoda, K., & Akashi, K. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.033 · Cited by 26
ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF
Triviai, I., Zeschke, S., Rentel, J., Spanakis, M., Scherer, T., Gabdoulline, R. R., Panagiota, V., Thol, F. R., Heuser, M., Stocking, C., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0159-0 · Cited by 27
Ogasawara, A., Matsushita, H., Tanaka, Y., Shirasugi, Y., Ando, K., Asai, S., & Miyachi, H. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.08.038 · Cited by 26
Rossi, C., Zini, R., Rontauroli, S., Ruberti, S., Prudente, Z., Barbieri, G., Bianchi, E., Salati, S., Genovese, E., Bartalucci, N., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12387 · Cited by 27
Self-citationSchmidt, D., Endres, C., Hoefflin, R., Andrieux, G., Zwick, M., Karantzelis, N., Staehle, H. F., Vinnakota, J. M., Duquesne, S., Jovein, M. M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3553 · Cited by 25
Self-citationYin, L.-H., Zheng, X., Li, H., Bi, L., Shi, Y., Ye, A.-F., Wu, J., & Gao, S. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.01.009 · Cited by 25
Al-Dewik, N. I. E., & Qoronfleh, M. W. (2019) · Advances in Public Health · doi:10.1155/2019/3807032 · Cited by 25
Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis
Kepp, O., Liu, P., Zhao, L., Plo, I., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1792037 · Cited by 26
Genetics of Myeloproliferative Neoplasms
Szybinski, J., & Meyer, S. C. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.12.002 · Cited by 28
CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes
Olschok, K., Han, L., Toledo, M. A. S., Böhnke, J., Graßhoff, M., Costa, I. G., Theocharides, A. P. A., Maurer, A., Schüler, H. M., Buhl, E. M., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.09.019 · Cited by 25
Essential Thrombocythemia in Children and Adolescents
Putti, M. C., Bertozzi, I., & Randi, M. L. (2021) · Cancers · doi:10.3390/cancers13236147 · Cited by 25
CALR mutation screening in pediatric primary myelofibrosis
An, W., Wan, Y., Guo, Y., Chen, X., Ren, Y., Zhang, J., Chang, L., Wei, W., Zhang, P., & Zhu, X. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25211 · Cited by 25
Profile of pacritinib and its potential in the treatment of hematologic disorders
Hatzimichael, E. C., Tsolas, E., & Briasoulis, E. C. (2014) · Journal of Blood Medicine · doi:10.2147/jbm.s51253 · Cited by 25
Bjørn, M. E., Andersen, C. L., Jensen, M. K., & Hasselbalch, H. C. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12332 · Cited by 25
Lundberg, P., Nienhold, R., Ambrosetti, A., Cervantes, F., Pérez‐Encinas, M., & Skoda, R. C. (2014) · Blood · doi:10.1182/blood-2014-01-550863 · Cited by 25
Pei, Y., Wu, Y., Wang, F., & Cui, W. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2712-0 · Cited by 25
Webb, M., Shibolet, O., Halpern, Z., Nagar, M., Amariglio, N., Levit, S., Steinberg, D. M., Santo, E., & Salomon, O. (2015) · Ultrasound Quarterly · doi:10.1097/ruq.0000000000000139 · Cited by 25
Martín–Llahí, M., Albillos, A., Bañares, R., Berzigotti, A., García‐Criado, Á., Genescà, J., Hernández–Gea, V., Llop‐Herrera, E., Masnou, H., Mateo, J., et al. (2017) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2017.03.011 · Cited by 25
Labastida-Mercado, N., Galindo-Becerra, S. L., Garcés‐Eisele, J., Colunga-Pedraza, P. R., Guzman-Olvera, V., Reyes‐Núñez, V., Ruiz‐Delgado, G. J., & Ruiz-Argüelles, G. J. (2015) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2014.12.002 · Cited by 24
Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs)
Dunbar, A. J., Nazir, A., & Levine, R. L. (2017) · Current Protocols in Pharmacology · doi:10.1002/cpph.23 · Cited by 27
Variations in MHC class I antigen presentation and immunopeptidome selection pathways
Zaitouna, A. J., Kaur, A., & Raghavan, M. (2020) · F1000Research · doi:10.12688/f1000research.26935.1 · Cited by 24
Pérez‐Encinas, M., Sobas, M., Gómez‐Casares, M. T., Blanco, A. A., Pereira, M. S. N., Raya, J. M., Andrade‐Campos, M., Álvarez‐Larrán, A., Lewandowski, K. C., Szukalski, Ł., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13561 · Cited by 24
Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia
Lampson, B. L., Gupta, A., Tyekucheva, S., Mashima, K., Petráčková, A., Wang, Z., Wojciechowska, N., Shaughnessy, C. J., Baker, P. O., Fernandes, S. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00269 · Cited by 24
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN
Usart, M., Hansen, N., Stetka, J., Fonseca, T. A., Guy, A., Kimmerlin, Q., Rai, S., Hao-Shen, H., Roux, J., Dirnhofer, S., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010950 · Cited by 24
Krähling, T., Balassa, K., Kiss, K. P., Bors, A., Bátai, Á., Halm, G., Egyed, M., Fekete, S., Reményi, P., Masszi, T., et al. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0805 · Cited by 24
The molecular basis of myeloid malignancies
Kitamura, T., Inoue, D., Okochi, N., Kato, N., Komeno, Y., Yang, L. U., Enomoto, Y., Doki, N., UCHIDA, T., Kagiyama, Y., et al. (2014) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.90.389 · Cited by 26
Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis
Lim, K., Lin, H., Chen, C. G., Wang, W., Chang, Y., Chiang, Y., Lin, C.-S., Su, N.-W., Su, Y., Lin, J., et al. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.11.011 · Cited by 24
CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence
Giona, F., Teofili, L., Capodimonti, S., Laurino, M., Martini, M., Marzella, D., Palumbo, G., Diverio, D., Foà, R., & Larocca, L. M. (2014) · Blood · doi:10.1182/blood-2014-04-572040 · Cited by 24
Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm
Wu, J., Zhang, L., Vaze, A., Lin, S., & Juhaeri, J. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.01.014 · Cited by 24
Wang, X., Haylock, D. N., Hu, C. S., Kowalczyk, W., Jiang, T., Qiu, J., Mosoyan, G., Wu, H., Marshall, N., Mascarenhas, J. O., et al. (2016) · Blood · doi:10.1182/blood-2015-10-674465 · Cited by 26
Loghavi, S., Pemmaraju, N., Kanagal‐Shamanna, R., Mehrotra, M., Medeiros, L. J., Luthra, R., Lin, P., Huh, Y. O., Kantarjian, H. M., Cortes, J. E., et al. (2015) · Blood · doi:10.1182/blood-2015-03-632893 · Cited by 24
Lindgren, M., Samuelsson, J., Nilsson, L., Knutsen, H., Ghanima, W., Westin, J., Johansson, P. L., & Andréasson, B. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13034 · Cited by 24
SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms
Aujla, A. S., Linder, K. J., Iragavarapu, C., Karass, M., & Liu, D. (2018) · Biomarker Research · doi:10.1186/s40364-018-0142-y · Cited by 25
The Myeloproliferative Neoplasm Landscape: A Patient’s Eye View
Petruk, C., & Mathias, J. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01314-0 · Cited by 25
Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish
Lim, K.-H., Chang, Y.-C., Chiang, Y.-L., Lin, H.-C., Chang, C.-Y., Lin, C.-S., Huang, L., Wang, W.-T., Chen, C.-J., Chou, W.-C., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.83 · Cited by 24
Gleitz, H. F., Kramann, R., & Schneider, R. K. (2018) · The Journal of Pathology · doi:10.1002/path.5078 · Cited by 23
Kędzierska, M., & Bańkosz, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237131 · Cited by 25
TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood
Coutinho, D. F., Monte-Mór, B. D. C. R., Vianna, D. T., Rouxinol, S. T., Batalha, A. B. W., Bueno, A. P. S., de Azevedo, A. M. B., Fernandez, T. D. S., Pombo‐de‐Oliveira, M. S., Gutiyama, L. M., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.07.005 · Cited by 24
Calreticulin Mutations in Myeloproliferative Neoplasms
Lavi, N. (2014) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10169 · Cited by 26
Harrison, C. N., Talpaz, M., & Mead, A. J. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1195501 · Cited by 23
Self-citationAraki, M., & Komatsu, N. (2017) · Cancer Science · doi:10.1111/cas.13327 · Cited by 23
Murine Models of Myelofibrosis
Jacquelin, S., Kramer, F., Mullally, A., & Lane, S. (2020) · Cancers · doi:10.3390/cancers12092381 · Cited by 26
Bennett, C., Lawrence, M., Guerrero, J. A., Stritt, S., Waller, A. K., Yan, Y., Mifsud, R. W., Ballester‐Beltrán, J., Baig, A., Mueller, A., et al. (2022) · Blood · doi:10.1182/blood.2021013113 · Cited by 23
Molecular Pathogenesis of Myeloproliferative Neoplasms
Rolles, B., & Mullally, A. (2022) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-022-00685-1 · Cited by 24
How we diagnose and treat essential thrombocythaemia
Alimam, S., Wilkins, B. S., & Harrison, C. N. (2015) · British Journal of Haematology · doi:10.1111/bjh.13605 · Cited by 25
Self-citationCo-existence ofJAK2V617F andCALRmutations in primary myelofibrosis
Zamora, L., Xicoy, B., Cabezón, M., Fernandez, C., Marcé, S., Vélez, P., Xandri, M., Gallardo, D., Millá, F., Feliú, E., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1015124 · Cited by 23
Alleviating anemia and thrombocytopenia in myelofibrosis patients
Cervantes, F., Correa, J. G., & Hernández‐Boluda, J. C. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1154452 · Cited by 23
Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis
Jeong, J. H., Lee, H. T., Seo, J. Y., Seo, Y. H., Kim, K., Kim, M. J., Lee, J. H., Park, J., Hong, J. S., Park, P.-W., et al. (2016) · Annals of Laboratory Medicine · doi:10.3343/alm.2016.36.4.291 · Cited by 23
Mutations in myeloproliferative neoplasms – their significance and clinical use
Schischlik, F., & Královics, R. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1380515 · Cited by 24
Driver mutations in primary myelofibrosis and their implications
Szuber, N., & Tefferi, A. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000406 · Cited by 23
The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance
Rumi, E., Trotti, C., Vanni, D., Casetti, I. C., Pietra, D., & Sant’Antonio, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238885 · Cited by 23
Haage, T. R., Charakopoulos, E., Bhuria, V., Baldauf, C. K., Korthals, M., Handschuh, J., Müller, P., Li, J., Harit, K., Nishanth, G., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01562-5 · Cited by 23
Self-citationLooking for CALR mutations in familial myeloproliferative neoplasms
Maffioli, M., Genoni, A. P., Caramazza, D., Mora, B., Bussini, A., Merli, M., Toni Giorgino, A., Casalone, R., & Passamonti, F. (2014) · Leukemia · doi:10.1038/leu.2014.33 · Cited by 22
Buduo, C. A. D., Balduini, A., & Moccia, F. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122055 · Cited by 22
Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
Klausen, U., Holmberg, S., Holmström, M. O., Jørgensen, N. G. D., Grauslund, J. H., Svane, I. M., & Andersen, M. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02264 · Cited by 22
The role of calreticulin mutations in myeloproliferative neoplasms
Araki, M., & Komatsu, N. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02800-0 · Cited by 22
Bernardi, S., & Farina, M. (2021) · Biology · doi:10.3390/biology10020105 · Cited by 23
Metadata
- Authors
- Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., Aziz, A., Godfrey, A. L., Hinton, J., Martincorena, I., Van Loo, P., Jones, A. V., Guglielmelli, P., Tarpey, P., Harding, H. P., Fitzpatrick, J. D., Goudie, C. T., Ortmann, C. A., Loughran, S. J., Raine, K., Jones, D. R., Butler, A. P., Teague, J. W., O'Meara, S., McLaren, S., Bianchi, M., Silber, Y., Dimitropoulou, D., Bloxham, D., Mudie, L., Maddison, M., Robinson, B., Keohane, C., Maclean, C., Hill, K., Orchard, K., Tauro, S., Du, M.-Q., Greaves, M., Bowen, D., Huntly, B. J. P., Harrison, C. N., Cross, N. C. P., Ron, D., Vannucchi, A. M., Papaemmanuil, E., Campbell, P. J., & Green, A. R.
- ORCID
- Nangalia, J.
- Massie, C.E.
- Baxter, E.J.
- Nice, F.L.
- Gundem, G.
- Wedge, D.C.
- Avezov, E.
- Kollmann, K.
- Kent, D.G.
- Godfrey, A.L.
- Hinton, J.
- Martincorena, I.
- Jones, A.V.
- Guglielmelli, P.
- Tarpey, P.
- Harding, H.P.
- Fitzpatrick, J.D.
- Loughran, S.J.
- Raine, K.
- Jones, D.R.
- Teague, J.W.
- McLaren, S.
- Hill, K.
- Orchard, K.
- Du, M.-Q.
- Greaves, M.
- Bowen, D.
- Huntly, B.J.P.
- Harrison, C.N.
- Cross, N.C.P.
- Ron, D.
- Vannucchi, A.M.
- Papaemmanuil, E.
- Campbell, P.J.
- Green, A.R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-12-19
- Volume
- 369
- Issue
- 25
- Pages
- 2391-2405
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3966280
- OpenAlex
- W2138709799
- Cited by
- 1,756
- References
- 40
- Citations by year
- 2026: 64 · 2025: 59 · 2024: 72 · 2023: 90 · 2022: 112 · 2021: 133 · 2020: 125 · 2019: 124 · 2018: 130 · 2017: 181 · 2016: 208 · 2015: 239 · 2014: 208 · 2013: 7
- FWCI
- 108.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- University of Salford Institutional Repository (University of Salford) (submittedVersion, cc-by)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Leukemia and Lymphoma Society
- Leukemia and Lymphoma Research
- University of Salford Manchester
- Wellcome Trust (079249, 100140, 093867, 084812)
- University Hospital Southampton NHS Foundation Trust
- Cancer Research UK (12526, 12765, 15488)
- National Institute for Health and Care Research (NF-SI-0512-10079)
- Kay Kendall Leukaemia Fund
- University of Southampton
- KU Leuven
- Università degli Studi di Firenze
- Associazione Italiana per la Ricerca sul Cancro
- Vlaamse regering
- Canadian Institutes of Health Research
- Medical Research Council
- Cambridge Institute for Medical Research, University of Cambridge
- NIHR Cambridge Biomedical Research Centre
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze
- Topics
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- calreticulin, CALR mutation, myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, myelofibrosis, myelodysplastic syndrome, endoplasmic reticulum chaperone, clonal evolution, hematopoietic stem and progenitor cells, somatic mutations
- MeSH terms
- Amino Acid Sequence, Bone Marrow Diseases, Exons, Humans, Leukemia, Myeloid, Molecular Sequence Data, Mutation, Myelodysplastic Syndromes, Neoplasms, Thrombocythemia, Essential, Polymerase Chain Reaction, Sequence Analysis, DNA, Calreticulin, Janus Kinase 2, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
